Press Release

« Back
Printer Friendly Version View printer-friendly version
Exelixis Announces May 5 Webcast of Presentation at the Deutsche Bank 35th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Apr 15, 2010 (BUSINESS WIRE) --Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company's president and chief executive officer, will present at the Deutsche Bank 35th Annual Health Care Conference at 9:20 a.m. EDT / 6:20 a.m. PDT on Wednesday, May 5, 2010 in Boston. Mr. Scangos will discuss the company's corporate strategy, development pipeline, financial results and financial outlook.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Investors:
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com
or
Exelixis, Inc.
Investors:
DeDe Sheel, 650-837-8231
Associate Director, Investor Relations
dsheel@exelixis.com